Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences (NASDAQ: ANIX) announced that the Mexican Institute of Industrial Property issued Patent No. 432748, covering key aspects of its breast cancer vaccine technology and extending IP protection in Mexico into the 2040s.

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that the Mexican Institute of Industrial Property issued Patent No. 432748, covering key aspects of its breast cancer vaccine technology and extending IP protection in Mexico into the 2040s.

The vaccine, licensed from Cleveland Clinic and targeting human α-lactalbumin, showed Phase 1 safety and protocol-defined immune responses in 74% of participants; Anixa is preparing a Phase 2 clinical trial and highlights continued expansion of its global patent estate.

Positive

• Mexican patent No. 432748 issued, extending protection into the 2040s
• Phase 1 showed vaccine safe and well tolerated at maximum tolerated dose
• 74% of Phase 1 participants elicited protocol-defined immune responses

Negative

• Phase 2 not yet initiated; clinical efficacy beyond immune response remains unproven
• Patent issuance is for Mexico specifically; full global protection depends on other jurisdictions

Argus Apr 29 session

-4.32% close to close Open Argus

Details

News Market Reaction – ANIX

On Apr 29, the day this news came out, ANIX closed 4.32% below the previous close.

Data tracked by StockTitan Argus for the Apr 29 session.

Market Context

This announcement highlights expansion of Anixa’s intellectual property for its breast cancer vaccin...

Analysis

This announcement highlights expansion of Anixa’s intellectual property for its breast cancer vaccine into Mexico, with protection running into the 2040s. It builds on Phase 1 data showing 74% of participants achieved protocol-defined immune responses and supports preparations for Phase 2. In context of ongoing net losses and reliance on external financing, including an active shelf registration, investors may watch future clinical readouts, partnering activity, and capital-raising steps to gauge program and balance-sheet evolution.

Key Figures

Immune response rate: 74% of participants Phase 1 primary endpoints: All primary endpoints met Patent protection horizon: Into 2040 +5 more

Immune response rate

74% of participants

Phase 1 breast cancer vaccine trial, all doses tested

Phase 1 primary endpoints

All primary endpoints met

Breast cancer vaccine Phase 1 trial

Patent protection horizon

Into 2040

Mexican patent covering breast cancer vaccine technology

Quarterly net loss

$2.565M

Three months ended January 31, 2026

Prior-year net loss

$3.184M

Three months ended January 31, 2025

R&D expenses

$1.102M

Quarter ended January 31, 2026

Cash & investments

$14.202M

Balance at January 31, 2026

ATM proceeds

$1.625M

Raised via at-the-market stock offering

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Conference presentation

   24h Move

   +2.6%

   ISCT 2026 presentation on ovarian cancer CAR-T lira-cel trial status.

2. Apr 09

   Investor conference

   24h Move

   +0.4%

   RedChip virtual conference featuring pipeline review and clinical updates.

3. Apr 07

   Investor conference

   24h Move

   +3.9%

   Water Tower conference presentation on strategy and trial highlights.

4. Apr 06

   Media interview

   24h Move

   +1.6%

   CEO interview outlining progress in immunotherapy programs.

5. Apr 01

   Clinical milestone

   24h Move

   +5.4%

   Final positive Phase 1 breast cancer vaccine data and Phase 2 manufacturing.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

triple-negative breast cancer, α-lactalbumin, Phase 1, maximum tolerated dose, +1 more

5 terms

triple-negative breast cancer medical

"greater late-stage breast cancerdiagnoses and higher triple-negative breast cancer incidence rates"

Triple-negative breast cancer is a type of breast cancer that lacks three common markers used to identify and treat the disease effectively. Because it doesn’t respond to some targeted therapies, it can be more difficult to treat and may have a more aggressive progression. This impacts the development of new treatments and can influence the outlook for healthcare companies involved in cancer research and pharmaceuticals.

α-lactalbumin medical

"vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation"

α-lactalbumin is a naturally occurring protein found in mammalian milk that supplies essential building blocks and supports nutrient absorption; think of it as a concentrated, high-quality protein ingredient used to boost the nutritional value of infant formula, medical nutrition and some supplements. Investors care because its use, purity, and supply affect product claims, regulatory approvals, patent positions and consumer demand in nutrition and health markets—factors that influence revenue and margins.

Phase 1 medical

"Positive Phase 1 results showed that the vaccine met all primary endpoints"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

maximum tolerated dose medical

"was safe and well tolerated at the maximum tolerated dose, and elicited"

Maximum tolerated dose is the highest amount of a substance, such as a medication or chemical, that can be used without causing unacceptable side effects or harm. It’s like finding the maximum speed you can drive without risking a ticket or accident. For investors, understanding this concept helps gauge how much risk or exposure is safe or sustainable in a given situation.

Phase 2 clinical trial medical

"Based on these findings, Anixa is moving forward with preparations for a Phase 2 clinical trial."

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expands global intellectual property coverage in markets with greater late-stage breast cancer
diagnoses and higher triple-negative breast cancer incidence rates

New patent will provide IP protection of Breast Cancer Vaccine in Mexico into 2040

SAN JOSE, Calif., April 29, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued Patent Number 432748, covering key aspects of the Company's breast cancer vaccine technology.

"This newly issued patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue clinical development in the U.S., our growing international patent estate further strengthens our ability to pursue global opportunities and potentially partner with larger pharmaceutical companies for worldwide commercialization."

Anixa's breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein vaccine strategy aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue. The vaccine was invented at Cleveland Clinic, and this patent—along with others related to this technology—has been exclusively licensed to Anixa Biosciences. Positive Phase 1 results showed that the vaccine met all primary endpoints, was safe and well tolerated at the maximum tolerated dose, and elicited protocol-defined immune responses in 74% of participants across all doses tested. Based on these findings, Anixa is moving forward with preparations for a Phase 2 clinical trial.

This patent issuance builds upon the Company's broad and expanding intellectual property portfolio, extending foundational patent protection for the breast cancer vaccine program into the 2040s in multiple jurisdictions throughout the world. By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-mexican-patent-covering-breast-cancer-vaccine-technology-302756543.html

SOURCE Anixa Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anixa (ANIX) announce about the Mexican patent on April 29, 2026?

Anixa announced issuance of Patent No. 432748 in Mexico, covering its breast cancer vaccine technology into the 2040s. According to the company, this strengthens its international intellectual property estate for future development and commercialization.

What were the Phase 1 results for Anixa's breast cancer vaccine (ANIX)?

Phase 1 met primary endpoints, was safe and well tolerated, and elicited immune responses in 74% of participants. According to the company, these findings support preparations for a Phase 2 clinical trial.

Does the Mexican patent mean global protection for Anixa's breast cancer vaccine (ANIX)?

The Mexican patent secures protection in Mexico into the 2040s, but global coverage depends on patents in other jurisdictions. According to the company, it is building a broader international patent estate.

How will the Mexican patent affect Anixa's commercialization plans for ANIX vaccine?

The patent adds IP protection that can support international development and partnership discussions. According to the company, it expects the expanded patent estate to aid potential licensing or commercialization talks with larger partners.

What is the next clinical step for Anixa's breast cancer vaccine (ANIX) after Phase 1?

Anixa is preparing to start a Phase 2 clinical trial based on Phase 1 safety and immune-response data. According to the company, Phase 2 preparations are underway to further evaluate clinical activity and dosing.